Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Witkin

Showing results (311-320 of 321) with videos related to

Pageof 33
Sort By:
Neuropharmacology|May 21, 2018
Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABA<sub>A</sub> receptors: Improved bioavailability enhances anticonvulsant efficacyJ M Witkin, J L Smith, X Ping, et al.
Neuropharmacology|September 28, 2013
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disordersLinda M Rorick-Kehn, Jeffrey M Witkin, Michael A Statnick, et al.
Pharmacology, Biochemistry, and Behavior|March 3, 2019
The α2,3-selective potentiator of GABA<sub>A</sub> receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in ratsJ M Witkin, R Cerne, P G Davis, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 27, 2019
Modulation of TARP <i>γ</i>8-Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic PainKelly L Knopp, Rosa Maria A Simmons, Wenhong Guo, et al.
Pharmacology Research & Perspectives|January 19, 2017
Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptorsJeffrey M Witkin, Linda M Rorick-Kehn, Mark J Benvenga, et al.
Nature Medicine|November 8, 2016
Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanismAkihiko S Kato, Kevin D Burris, Kevin M Gardinier, et al.
Neuropharmacology|November 6, 2017
Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disordersRobert F Bruns, Stephen N Mitchell, Keith A Wafford, et al.
Journal of Medicinal Chemistry|April 13, 2016
Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8Kevin M Gardinier, Douglas L Gernert, Warren J Porter, et al.
Bioorganic & Medicinal Chemistry Letters|November 13, 2016
Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depressionBruce A Dressman, Eric G Tromiczak, Mark D Chappell, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2010
N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changesMatthew J Fell, Jeffrey M Witkin, Julie F Falcone, et al.
Pageof 33

Showing results (311-320 of 321) with videos related to

Sort By:
Pageof 33
Neuropharmacology|May 21, 2018
Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABA<sub>A</sub> receptors: Improved bioavailability enhances anticonvulsant efficacyJ M Witkin, J L Smith, X Ping, et al.
Neuropharmacology|September 28, 2013
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disordersLinda M Rorick-Kehn, Jeffrey M Witkin, Michael A Statnick, et al.
Pharmacology, Biochemistry, and Behavior|March 3, 2019
The α2,3-selective potentiator of GABA<sub>A</sub> receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in ratsJ M Witkin, R Cerne, P G Davis, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 27, 2019
Modulation of TARP <i>γ</i>8-Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic PainKelly L Knopp, Rosa Maria A Simmons, Wenhong Guo, et al.
Pharmacology Research & Perspectives|January 19, 2017
Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptorsJeffrey M Witkin, Linda M Rorick-Kehn, Mark J Benvenga, et al.
Nature Medicine|November 8, 2016
Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanismAkihiko S Kato, Kevin D Burris, Kevin M Gardinier, et al.
Neuropharmacology|November 6, 2017
Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disordersRobert F Bruns, Stephen N Mitchell, Keith A Wafford, et al.
Journal of Medicinal Chemistry|April 13, 2016
Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8Kevin M Gardinier, Douglas L Gernert, Warren J Porter, et al.
Bioorganic & Medicinal Chemistry Letters|November 13, 2016
Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depressionBruce A Dressman, Eric G Tromiczak, Mark D Chappell, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2010
N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changesMatthew J Fell, Jeffrey M Witkin, Julie F Falcone, et al.
Pageof 33